Plus therapeutics announces positive interim data from respect™ phase 1 clinical trial in recurrent glioblastoma

Investigational drug rnl ™ d eliver s u p to fifteen t imes the a bsorbed d ose of r adiation c ompared to standard e xternal b eam r adiation t herapy

PSTV Ratings Summary

PSTV Quant Ranking